Annie De Groot News Today

/PRNewswire/ -- EpiVax, Inc. ("EpiVax"), an internationally recognized leader in the field of immunogenicity, today announced that Eisai Co. Ltd. ("Eisai") has...

/PRNewswire/ -- EpiVax, Inc. ("EpiVax") is celebrating its 25th birthday by renewing the companys commitment to improving human health everywhere while...

PROVIDENCE, R.I., May 17, 2023 /PRNewswire/ -- EpiVax, Inc. ("EpiVax") is celebrating its 25th birthday by renewing the company's commitment to improving human health everywhere while highlighting

PROVIDENCE, R.I., May 17, 2023 /PRNewswire/ -- EpiVax, Inc. (EpiVax) is celebrating its 25th birthday by renewing the companys commitment to im...

Press release content from PR Newswire. The AP news staff was not involved in its creation.

/PRNewswire/ -- EpiVax, Inc. ("EpiVax") announces the establishment of the Vax Gives Back Fund at the Rhode Island Foundation, a step to continue the strong...

/PRNewswire/ -- EpiVax, Inc. ("EpiVax") announces the establishment of the Vax Gives Back Fund at the Rhode Island Foundation, a step to continue the strong...

/PRNewswire/ -- EpiVax Therapeutics, Inc. ("EVT"), an emerging biotechnology company, today announced that an abstract highlighting its Ancer® platform will be...

Pr-newswirePROVIDENCE, R.I., May 13, 2021 /PRNewswire/ -- EpiVax Therapeutics, Inc. (EVT) announces the publication [...]

Share this article Share this article Scientific Reports. This study demonstrates a superior method of survival analysis for cancer patients using EVTs Ancer platform. EVT spun-off from EpiVax, Inc. in 2017 to apply EpiVax tools to clinical research. Built on validated in silico tools EpiMatrix and JanusMatrix, Ancer analyzes individual cancer mutanomes to define the presence of T cell epitopes likely to be immunogenic. The concept behind Ancer is that the presence of a mutation alone is not ...